Immunoproteasome subunits LMP2 and LMP7 downregulation in primary malignant melanoma lesions: Association with lack of spontaneous regression

Melanoma Research

Volumn 13, Issue 4, 2003, Pages 371-377

  Dissemond, Joachim ^a   Goette, Petra ^a   Moers, Janet ^a   Lindeke, Anette ^a   Goos, Manfred ^a   Ferrone, Soldano ^b   Wagner, Stephan N ^a,c  

^a University School of Medicine   (Germany)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c Universitatsklinik fur Dermatologie   (Austria)

Author keywords

LMP; Melanoma; MHC class I; Regression

Indexed keywords

IMMUNOPROTEASOME; LOW MOLECULAR WEIGHT PROTEIN 2; LOW MOLECULAR WEIGHT PROTEIN 7; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEASOME; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME SUBUNIT; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MELANOCYTIC NEVUS; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; SKIN BIOPSY; SKIN TUMOR;

CYSTEINE ENDOPEPTIDASES; DOWN-REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MULTIENZYME COMPLEXES; NEOPLASM REGRESSION, SPONTANEOUS; NEVUS, PIGMENTED; SKIN NEOPLASMS; STATISTICS;

EID: 0041866537     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200308000-00006     Document Type: Article

References (26)

1. Pamer E, Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol 1998; 16:323-358.
2. Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 1999; 17: 739-779.
3. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994; 78:761-771.
4. Cerundolo V, Benham A, Braud V, Mukheriee S, Gould K, Macino B, et al. The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells. Eur J Immunol 1997; 27:336-341.
5. Craiu A, Akopian T, Goldberg A, Rock KL. Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. Proc Natl Acad Sci USA 1997; 94:10850-10855.
6. Gallimore A, Hengartner H, Zinkernagel R. Hierarchies of antigen-specific cytotoxic T-cell responses. Immunol Rev 1998; 164:29-36.
7. Tanaka K, Chiba T. The proteasome: a protein-destroying machine. Genes Cells 1998; 3:499-510.
8. Groettrup M, Khan S, Schwarz K, Schmidtke G. Interferon-γ inducible exchanges of 20S proteasome active site subunits: why? Biochimie 2001; 83:367-372.
9. Driscoll J, Brown MG, Finley D, Monaco JJ. MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature 1993; 365:262-264.
10. Gaczynska M, Rock KL, Goldberg AL. Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 1993; 365:264-267.
11. Cardozo C, Kohanski RA. Altered properties of the branched chain amino acid-preferring activity contribute to increased cleavages after branched chain residues by the 'immunoproteasome'. J Biol Chem 1998; 273:16764-16770.
12. Fehling HJ, Swat W, Laplace C, Kühn R, Rajewsky K, Müller U, Boehmer H. MHC class I expression in mice lacking the proteasome subunit LMP-7. Science 1994; 265:1234-1237.
13. van Kaer L, Ashton-Rickardt PG, Eichelberger M, Gaczynaka M, Nagashima K, Rock KL, et al. Altered peptidase and viral-specific T cell response in LMP2 mutant mice. Immunity 1994; 1:533-541.
14. Gileadi, U, Moins-Teisserenc HT, Correa I, Booth BL Jr, Dunbar PR, Sewell AK, et al. Generation of an immunodominant CTL epitope is affected by proteasome subunit composition and stability of the antigenic protein. J Immunol 1999; 163:6045-6052.
15. Sijts AJ, Standera S, Toes RE, Ruppert T, Beekman NJ, van Veelen PA, et al. MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells. J Immunol 2000; 164:4500-4506.
16. Morel S, Levy F, Burlet-Schlitz O, Brasseur F, Probst-Kepper M, Peitrequin AL, et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000; 12:107-117.
17. Wagner SN, Schultewolter T, Wagner C, Briedigkeit L, Becker JC, Kwasnicka HM, Goos M. Immune response against human primary malignant melanoma: a distinct cytokine mRNA profile associated with spontaneous regression. Lab Invest 1998; 78:541-550.
18. Clark WH Jr, Elder DH, Guerry DP, Braitmen LE, Trock BJ, Schultz D. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81:1893-1904.
19. Dellaratta D, Hicklin DJ, Kishore R, Kageshita T and Ferrone S. Characterization of rabbit antisera elicted with human LMP2- and LMP1-specific peptides and recombinant proteins. Tissue Antigens 1997; 50:567-575.
20. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma. Am J Pathol 1999; 154:745-754.
21. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, Macdonald S, et al. Immunoenzymatic labeling of monoclonal antibodies of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complex). J Histochem Cytochem 1984; 32:219-229.
22. Shi SR, Imam SA, Young L, Cote R, Taylor CR. Antigen retrieval immunhistochemistry under the influence of pH using monoclonal antibodies. J Histochem Cytochem 1995; 43:193-201.
23. Merz H, Malisius R, Mannweiler S, Zhou R, Hartmann W, Orscheschek K, et al. ImmunoMax - a maximized immunohistochemical method for the retrieval and enhancement of hidden antigens. Lab Invest 1995; 73:149-156.
24. Sewell AK, Price DA, Teisserenc H, Booth BL Jr, Gileadi U, Flavin FM, et al. IFN-gamma exposes a cryptic cytotoxic T lymphocyte epitope in HIV-1 reverse transcriptase. J Immunol 1999; 162:7075-7079.
25. Sijts AJ, Ruppert T, Rehermann B, Schmidt M, Koszinowski U, Kloetzel PM. Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes. J Exp Med 2000; 191:503-514.
26. Hallermalm K, Seki K, Wie C, Castelli C, Rivoltini L, Kiessling R, Levitskaya J. Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface. Blood 2001; 98:1108-1115.